Product Images Losartan Potassium Tablets, 50 Mg

The text is a table showing the percentage of patients with fatal and non-fatal stroke who were treated with Atenolol and Losartan Potassium. The table also provides the adjusted risk reduction percentages and p-values for both treatments. The Study Month column indicates the duration of the study.*

This is a graph (Figure 3) that shows the primary endpoint events in demographic subgroups for patients taking Losartan and Atenolol for stroke prevention. The graph is divided into different subgroups such as age, gender, race, diabetes, and history of CVD. The primary endpoint is a composite stroke that is fatal or non-fatal. The graph displays the number of events, the rate of events, and the hazard ratio for both Losartan and Atenolol. The symbols on the graph are proportional to sample size, and the hazard ratio is adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy. The text provides additional information on the subgroup breakdowns and results that favor Losartan or Atenolol.*

This text is presenting data related to a clinical trial comparing the risk reduction of Losartan Potassium with Placebo. The percentage of patients who experienced an event is shown as 80%, and the risk reduction rate is 16.1%. Unfortunately, there is no context or information provided about the type of event, the nature of the clinical trial, or the units of measurement.*

This is a pharmaceutical label for Losartan Potassium tablets with a strength of 50mg. The label provides dosage instructions and storage precautions, including protecting from light and keeping the container tightly closed. The National Drug Code (NDC) for the product is 63629-9192-01, and it is for prescription use only.*